Ownership
Private
Employees
~91
Therapeutic Areas
Other
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Generic drugs

Novitium Pharma General Information

Novitium Pharma is a U.S.-based pharmaceutical company founded in 2016 that specializes in the development, manufacturing, and distribution of niche generic products[6]. The company was acquired by ANI Pharmaceuticals on November 18, 2021, for $210 million[7]. Novitium has developed a growing commercial product portfolio spanning diverse dosage forms and therapeutic categories and has filed over 20 ANDAs (Abbreviated New Drug Applications) with the FDA[5]. The company prides itself on manufacturing its products in the USA at its state-of-the-art facility[1][6]. With approximately 91 employees and an estimated annual revenue of $2 million as of 2025, Novitium continues to invest in producing affordable, high-quality medications to fulfill the needs of pharmacists, patients, and communities[5][6]. The company is headquartered in East Windsor, New Jersey[4][5].

Contact Information

Primary Industry
Biotech
Corporate Office
East Windsor, New Jersey
United States

Drug Pipeline

famotidine
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Novitium Pharma's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Novitium Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Novitium Pharma's complete valuation and funding history, request access »

Novitium Pharma Financial Metrics